Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Shanghai MicroPort MedBot (Group) Co's Return-on-Tangible-Equity or its related term are showing as below:
HKSE:02252'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -267.7 Med: -74.31 Max: -28.51
Current: -62.26
During the past 7 years, Shanghai MicroPort MedBot (Group) Co's highest Return-on-Tangible-Equity was -28.51%. The lowest was -267.70%. And the median was -74.31%.
HKSE:02252's Return-on-Tangible-Equity is ranked worse than 83.62% of 757
companies
in the Medical Devices & Instruments industry
Industry Median: 4.16
vs HKSE:02252: -62.26
Shanghai MicroPort MedBot (Group) Co (HKSE:02252) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Shanghai MicroPort MedBot (Group) Co Return-on-Tangible-Equity Related Terms
Shanghai MicroPort MedBot (Group) Co Return-on-Tangible-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai MicroPort MedBot (Group) Co Return-on-Tangible-Equity Chart
HKSE:02252 vs ABT, SYK, MDT: Return-on-Tangible-Equity Comparison
For the Medical Devices subindustry, Shanghai MicroPort MedBot (Group) Co's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai MicroPort MedBot (Group) Co Return-on-Tangible-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Shanghai MicroPort MedBot (Group) Co's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Shanghai MicroPort MedBot (Group) Co's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -58.40% mean?
Shanghai MicroPort MedBot (Group) Co (HKSE:02252) has a Return-on-Tangible-Equity of -58.40% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Shanghai MicroPort MedBot (Group) Co and its competitors. According to the industry distribution chart, Shanghai MicroPort MedBot (Group) Co ranks #633 out of 757 companies in the Medical Devices & Instruments industry, placing it in the top 83.6%.
Is Shanghai MicroPort MedBot (Group) Co's Return-on-Tangible-Equity too high?
Shanghai MicroPort MedBot (Group) Co's current Return-on-Tangible-Equity is -58.40%. Based on the distribution chart, Shanghai MicroPort MedBot (Group) Co ranks #633 out of 757 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Shanghai MicroPort MedBot (Group) Co has a GF Score™ of 45/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Shanghai MicroPort MedBot (Group) Co's Return-on-Tangible-Equity compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Shanghai MicroPort MedBot (Group) Co ranks #633 out of 757 companies for Return-on-Tangible-Equity. This places Shanghai MicroPort MedBot (Group) Co in the lower half of its industry. The industry median Return-on-Tangible-Equity is 4.16. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Devices & Instruments company?
The median Return-on-Tangible-Equity among Medical Devices & Instruments companies is 4.16, based on 757 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Shanghai MicroPort MedBot (Group) Co and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Equity is 4.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai MicroPort MedBot (Group) Co's current Return-on-Tangible-Equity is -58.40%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai MicroPort MedBot (Group) Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai MicroPort MedBot (Group) Co (HKSE:02252) is currently considered Possible Value Trap. The stock's GF Value™ is HK$81.81, compared to a current price of HK$25.48 — trading 68.9% below its estimated fair value. The current Return-on-Tangible-Equity is -58.40%. Shanghai MicroPort MedBot (Group) Co's overall GF Score™ is 45/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Shanghai MicroPort MedBot (Group) Co (HKSE:02252), the current Return-on-Tangible-Equity is -58.40% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai MicroPort MedBot (Group) Co (HKSE:02252) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai MicroPort MedBot (Group) Co stock appears to be undervalued.
The current stock price of HK$25.48 is trading 68.9% below its estimated GF Value™ of HK$81.81.
GuruFocus considers Shanghai MicroPort MedBot (Group) Co to be Possible Value Trap.
Key valuation signals for HKSE:02252:
Return-on-Tangible-Equity: -58.40%
GF Value™: HK$81.81 vs. price of HK$25.48 (68.9% below fair value)
No single metric tells the full story. See the HKSE:02252 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai MicroPort MedBot (Group) Co Ltd is a surgical robot company dedicated to designing, developing, and commercializing surgical robots to assist surgeons in performing complex surgical procedures. The business of the company covers various surgical specialties of laparoscopic, orthopedic, panvascular, natural orifice, and percutaneous surgical procedures, and has accumulated several products at various stages as those in development, clinical trials, registration, and commercialisation. The company derives revenue principally from the sales of surgical robot systems, instruments, and accessories, and the provision of services through appointed distributors. Geographically, it derives maximum revenue from the People's Republic of China.
45GF Score
Get the complete analysis for HKSE:02252
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02252 has been successfully added to your 
